VEGFA overexpression of VEGF-Axxxa — variant · CancerIndex

Variant · Expression

VEGFA overexpression of VEGF-Axxxa

CI-VAR-00005024Explore in graph →CIViC 3322

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
VEGFA overexpression of VEGF-Axxxa	Bevacizumab	Predictive	B	Supports Sensitivity Response	4	submitted	EID9290 In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC) PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.